BTIG Research Reaffirms “Buy” Rating for Misonix (NASDAQ:MSON)
BTIG Research restated their buy rating on shares of Misonix (NASDAQ:MSON) in a research note released on Thursday, AnalystRatings.com reports. They currently have a $27.00 target price on the medical equipment provider’s stock.
MSON has been the topic of several other reports. BidaskClub upgraded shares of Misonix from a buy rating to a strong-buy rating in a research report on Wednesday, July 3rd. TheStreet cut shares of Misonix from a c- rating to a d rating in a research report on Thursday, June 20th. ValuEngine cut shares of Misonix from a buy rating to a hold rating in a research report on Thursday, August 1st. Finally, Canaccord Genuity reiterated a buy rating and issued a $30.00 price target (up from $24.00) on shares of Misonix in a research report on Thursday. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $28.33.
Shares of Misonix stock opened at $20.82 on Thursday. The company’s 50-day moving average price is $23.77 and its two-hundred day moving average price is $21.09. Misonix has a 52 week low of $13.19 and a 52 week high of $27.54.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Read More: Capital Gains
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.